Xeltis’ is one of seven nominees for the Swiss Medtech Award; for its restorative pulmonary heart valve technology. The award will be presented to one of three finalists on June 12, 2018 at Swiss Medtech Day.
The Swiss Medtech award recognizes outstanding achievements in the Swiss medical technology industry. The criteria for nomination include, among others, the development of groundbreaking technologies or processes.
Xeltis’ restorative heart valves are designed to enable the patient’s body to form a new valve with its own tissue. This novel approach in heart valve therapy may help reduce the risk of further interventions and it is currently being assessed in Europe, Asia and in the USA as part of clinical trials.
Click here for more information on the Swiss Medtech Award.